Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Poolbeg Pharma Plc | LSE:POLB | London | Ordinary Share | GB00BKPG7Z60 | ORD 0.02P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.05 | 0.66% | 7.65 | 64,978 | 08:19:14 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 7.60 | 7.70 | 7.70 | 7.65 | 7.70 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | -3.93M | -0.0079 | -9.68 | 38M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:19:03 | O | 50,000 | 7.61 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/11/2024 | 18:26 | ALNC |  Poolbeg Pharma granted US patent for influenza treatment |
| 20/11/2024 | 07:00 | UK RNS | Poolbeg Pharma PLC POLB 001 Patent Granted in United States |
| 06/11/2024 | 07:00 | UK RNS | Poolbeg Pharma PLC POLB 001 data to be presented at ASH |
| 18/9/2024 | 06:00 | UK RNS | Poolbeg Pharma PLC Interim results for the six months to 30 June 2024 |
| 27/8/2024 | 06:00 | UK RNS | Poolbeg Pharma PLC H.C. Wainwright Global Investment Conference |
| 12/8/2024 | 12:28 | UK RNS | Poolbeg Pharma PLC Holding(s) in Company |
| 26/7/2024 | 17:59 | ALNC | EARNINGS AND TRADING: Man Group profit rises; Petershill AUM increases |
| 26/7/2024 | 06:00 | UK RNS | Poolbeg Pharma PLC Voluntary Delisting from OTCQB Market |
| 10/7/2024 | 06:00 | UK RNS | Poolbeg Pharma PLC Notification of Major Holdings |
| 02/7/2024 | 06:00 | UK RNS | Poolbeg Pharma PLC Change of Registered Address |
Poolbeg Pharma (POLB) Share Charts1 Year Poolbeg Pharma Chart |
|
1 Month Poolbeg Pharma Chart |
Intraday Poolbeg Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 20/11/2024 | 22:26 | Poolbeg Pharma | 3,751 |
| 24/10/2022 | 15:20 | Polb | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 08:19:04 | 7.61 | 50,000 | 3,805.00 | O |
| 08:15:47 | 7.60 | 236 | 17.94 | O |
| 08:15:47 | 7.80 | 100 | 7.80 | O |
| 08:15:47 | 7.80 | 128 | 9.98 | O |
| 08:15:47 | 7.60 | 235 | 17.86 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Poolbeg Pharma Daily Update Poolbeg Pharma Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker POLB. The last closing price for Poolbeg Pharma was 7.60p.Poolbeg Pharma currently has 500,000,000 shares in issue. The market capitalisation of Poolbeg Pharma is £38,250,000. Poolbeg Pharma has a price to earnings ratio (PE ratio) of -9.68. This morning POLB shares opened at 7.70p |
Posted at 06/11/2024 09:20 by burtond1 https://www.londonst |
Posted at 14/10/2024 08:52 by malcolmz1 You can't filter the facts. This has burnt 10m since it listed and is sitting at over 20% discount to ipo price. Another example of someone who hasn't banked a penny when the share price was up 50%. Some people never learn. |
Posted at 13/10/2024 08:54 by pogue Peterrr3I go to plenty events to window shop, going to an event does not mean there is a fundraise going to happen, I suggest you are taking one presentation out of context and extrapolating to the moon. I don’t see where they need the funds to be honest. They started out 3 years ago with around £20 million and now have around £10 million and are trailing POLB001 with 2 pharma companies’ drugs which suggests they are in advanced talks as if they goto human trial, they have done the In Vivo animal trial, there would have to be a contract signed setting out the partnership/selling deal should the result be positive as is normal in these situations in industry. No pharma company would want to increase the value of a 3rd party drug by proving it successful without having a price fixed beforehand. Why fundraise when you are that close to a massive monetisation of your lead asset? Why are they trying to find an orphan drug to sell? Well to make money perhaps? POLB have a pipeline of drugs they develop and sell/partner. Pentoxifylline has past phase II so they don’t need to put it through a trial. I don’t know what the deal will be with the owner but I cannot see POLB buying it unless they have a buyer. I suggest the most likely is a partnership where POLB help sell the drug and share in the profits. This is a capital light company they don’t spend money unless they have to bringing on drugs, have you seen the very small quantities of cash they have spent on the existing drugs in the pipeline? The fact they have spent only £10 million or so over 3 years is a clue. As I said I have listened to the Liam Trimble go on about POLB’s encapsulation tech being used in a trail later this year all 43 seconds off it and did not get excited about at the time as an oral encapsulation trial was being planned from the beginning of this year and was initially down to happen July/August so not seeing what the issue is, nothing new in it. The cost will be small and is being tested for use with another company’s drug they will contribute in some way same as those pharmas running the POLB001 trials did. The trial is very simple for encapsulation. Volunteer comes into medical establishment, pops a pill come backs next day to get a blood test to see if the drug has dispersed in their system, you really think they need a fundraise for this and it hasn’t been planned for? It is not the drug that’s being tested its oral encapsulation so not dangerous or expensive do you really think a sudden fundraise is needed for that as it has been planned for for a long time? As I said POLB does not have an obesity drug it’s the encapsulation that is being trailed. Should the trial work then there is a vast market out there for oral encapsulation way outside obesity drugs. Really cant see what you are going on about there. So to summarise why do you think they need a fundraise when they are getting close to a deal on POLB001? Oral encapsulation has been planned for trial for a long time and is not expensive to do. Pentoxifylline does not belong to POLB, they have an option on it and is past phase II so what cash do they need to spend as the option will more than likely be on a deal to sell in partnership with current owner and they dont need to conclude the deal if they see no buyers. |
Posted at 18/9/2024 10:14 by pogue My typing was a bit rushed had a meeting to prep so my post should have read 'I assume you are not invested'.Anyway sugar coating are what CEOs are paid to do. If you want real info and are good at talking, I suggest going to an event and speaking to CEOs I do it regularly, am going to one tomorrow night, and you can get amazing information from how they answer a question if set correctly. Its an artform kind of like interrogation. Lots can be deduced from tone, body language and avoidance of points. In the case of POLB I see massive positives which I highlighted and these are in the short term. Highlighting minor negatives further down the pipeline is pointless as the company's share price will be decided on POLB001 and encapsulation in the short term and both are moving forward, I expect POLB001 to have the in human trials with cancer drugs soon and encapsulation should be up for sale/partnering in the New Year after human trials. If you are investing these are the points to focus on as those are what will give the share price a massive lift. If you are not invested then looking at the negatives and trying to spin them out as massive problems is what you do but you wont make money that way. |
Posted at 13/9/2024 14:03 by sikhthetech 2350220,This is the pump/dump gang at their best. They'll trade hundreds of small buys to push the share price higher and make you believe there's investors buying in. As the pump/dump gang sell, the share price falls, the gang convince gullible PIs to stay invested, 'news soon' etc, so gullible investors buy thinking the price is about to turn... Once things settle down, the cheerleader will arrive controlling the narrative, telling gullible PIs, in hindsight, what's happened. The gang will then agree with the cheerleader, rinse and spin. |
Posted at 03/8/2024 07:40 by baldrick1 My weekend argument is polb current share price is way overvalued .. no revenues, not a hint of any large pharma eager to license polb1 and cash down to merely 12 million from the highs of 20 million.A Placings for new funding could be the next big news coming out..aimho |
Posted at 02/7/2024 11:38 by pogue peterr3I will spell it out as I feel you were listening to the wrong bits there. The lead asset of POLB is POLB001 and will be the first monetized. 2 pharmas are interested in it as their new very powerful cancer drugs have the side effect of cytokine storms. Cytokline storms mean that patients tie up hospital beds in cancer units thus reducing the amount of drugs that can be administered so huge incentive to find a drug that prevents them happening, like POLB001. Hugh incentive there for a phamra to partner with POLB if POLB001 works. Now as a stand alone drug POLB001 does the job all they have to do is prove it works whilst other drugs are in a patients system. The 2 pharmas have already given POLB the drugs, worth £millions, to run the trial and will pay for the trial as the market for their drug is 10s of $billions. We await the trial date how long do you think the pharmas are going to wait with a prize of that size? Now the other part you need to research is what normally happens in these situations ie a drug going to trial with another and what the trial contract normally says baring in mind that if it proves successful the value of POLB001 goes through the roof. Clue the contract has a section on that and I strongly suggest that is the reason for the delay as its a very important section.. Sorry if very direct but you have missed the point completely of what is happening and this board has so many halfwit derampers who avoid basic facts that I treat posters I dont know with suspicion. |
Posted at 07/5/2024 21:47 by elrico Sicko, It's unjust to judge others by your own standards. I consistently reveal my sale/top slice a minimum of two trading days in advance if I possess a stated position. Additionally, not everyone can dedicate hundreds of hours each month; some have demanding careers, families, etc. Nevertheless, I do concur that whenever feasible, investors ought to DTOR, such as reviewing independent analyses. You might label these individuals as "cheerleaders" to fit your narrative. Relying on your analyses could have been risky with HVO and POLB, yet one thing is certain, you have been consistently inaccurate.I recall you singing the pump & dump song when POLB share price was c6p. Had anyone been put off by your constant trashing, they would have missed out on healthy gains. I do hope you are pleased with yourself. Instead of just highlighting investors' losses, why not provide some balance by sharing your own? As flawless as you may seem compared to Buffet and Munger, I'm fairly certain you've also had your fair share of failed investments. I know I have over the past 30+ years. Play nice! |
Posted at 15/2/2024 11:07 by 1gw parsons4 - well if we take CF's relatively recent linkedin post at face value (and I know some don't) about aiming to complete the IPO of POLB on Nasdaq later this year then I can understand his desire to get the share price up ahead of setting the price for that.If I were then to look at even more recent discussion of acquiring and commercialising rare/orphan disease drugs, I might start to think that there could be a plan to acquire or reverse in to an existing Nasdaq-quoted company that was low on cash but had some promising approved or late phase drugs, particularly if those drugs were in the oncology space that would fit with trials of POLB001 for immunotherapy-induce Whether IPO'ing directly as POLB, or raising cash following, or as part of, an acquisition/reverse, a high shareprice would be a lot more useful than a low shareprice in terms of minimising the dilution of existing shareholders. |
Posted at 07/2/2024 18:54 by troutisout We have all seen the great rise in HVO over the last 7 months, starting with contract wins in late June and July, then the positive trading update at the end of July and of course, what was the start of Institutional buying.Before that POLB mirrored HVO quite closely, deviating a little every now and then and then one or the other adjusting back. POLB showed the way in late Summer/Autumn 2022 with HVO mirroring the moves several weeks later. Then HVO leapt ahead of POLB in the late Summer/Autumn 2023, but the news of the Amryt team joining propelled POLB back up there again in November. As we went into the Christmas period and the New Year HVO has hit the rocket boosters with more contract wins and a really good TU. POLB has dithered and dropped slightly. I don't think the relationship between the two has broken (although the II buying in HVO will have diluted the relationship where many of the holders of HVO also held POLB). So we wait to see if POLB catches up again, it certainly looks a few weeks behind but the correlation has been strong up to now.... POLB black, HVO Blue, HVO overlaid on POLB from the first day of POLB trading free stock charts from uk.advfn.com |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
